Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Investigational therapy enhances breast cancer treatments, preclinical studies show
January 19th, 2006
Introgen Therapeutics, Inc. (INGN) reported that preclinical studies show its investigational cancer therapy INGN 241 reduced tumor growth and increased tumor cell death in various breast cancer treatment regimens. These data were published in the journal Cancer Gene Therapy and also were described in three presentations at the 2005 San Antonio Breast Cancer Symposium. Introgen researchers and their collaborators at The University of Texas M.D. Anderson Cancer Center conducted the studies. The article in Cancer Gene Therapy describes the anticancer activity of mda-7, the active component of INGN 241, in nine breast cancer tumors....
Source: Women's Health Weekly (2006-01-19)
|
